Mission
We want to change the very approach to ageing
BIO+ Longevica™ is a science-backed platform designed to develop and personalise treatments for age-related diseases, neurodegeneration, metabolic disorders and chronic inflammation. Our start-up's mission is to make active longevity accessible and personalised by harnessing the power of plants, AI algorithms and knowledge of cell biology.
We don't just prolong life. We prolong clarity, energy and resilience.
Ageing is not a death sentence, but a call to action
Our products are based on proven mechanisms: SIRT1, AMPK, NRF2, CB2 receptors, and others. We strive not only to prolong life, but to make it active, clear, and sustainable.
According to data from the European Commission, in 2023 the average life expectancy in the EU was over 81 years, but only 65–66 years of that was spent in good health. The remaining years are marked by chronic diseases, dementia, diabetes and fatigue. We believe that this gap can be closed by acting at the cellular regulation level — through science, biointegration and prevention.
What we offer
Intelligent phytotherapy + personalisation + digital ecosystem
Scientific transparency strategy
Every ingredient we use has scientific justification and proven bioavailability. We provide links to studies and do not hide our formulas.
Digital selection with AI
The BIO+ Advisor™ platform personalises the composition based on your data — biomarkers, symptoms, lifestyle.
New generation formulas
Biologically active complexes based on flavonoids, terpenes and alkaloids, validated by international research.
What we base our claims on
EGCG (green tea):
activates SIRT1 and AMPK, reduces inflammation, and extends lifespan in preclinical models by 25%.
β-caryophyllene:
selectively activates CB2 receptors, reduces neuroinflammation.
Mircene, quercetin, apigenin, galangin, silymarin:
have a complex effect on mitochondria, NF-κB and oxidative stress levels.
BioMatrix™ ion exchange matrices:
bind toxins, mycotoxins and heavy metals with up to 87% efficiency (in vitro data, 2023–2024).
We are developing more than 70 phytoactives, which we will validate, certify and include in the 2026-2029 production programme.
Who is behind the project?
BIO+ Longevica™ was founded by scientists, bioengineers, and digital strategists who came together around the idea that phytotherapy can and should be evidence-based, personalised, and technologically adaptive. We work with research centres and experts in Europe, using developments from OpenAI, Nvidia and Microsoft Azure to create BioPlus™ — a digital platform for ageing prevention.
Ludmila Chyrva
CEO & Founder
Drives strategic vision, budget oversight, and go-to-market scale-up.
Dr. Margarita Suleiman
Head of R&D
Leads scientific strategy across pharmaceutical chemistry, natural product research, and molecular design.
Prof. Dr. Yana Emchenko
Clinical Director
Leads in clinical validation, immunology, and personalized therapy
Alex Schmidt
Digital Advisor & Founder
Architect of the BIOPLUS™ platform, specializing in AI integration and biomarker analytics.
‘BIO+ Longevica™ is not just a brand. It is science, care and understanding of how the human body ages and how we can gently counteract this process.’
— Project team